MX2019014483A - Regimenes de dosificación de antagonistas de hormona liberadora de gonadotropina para el tratamiento de endometriosis. - Google Patents
Regimenes de dosificación de antagonistas de hormona liberadora de gonadotropina para el tratamiento de endometriosis.Info
- Publication number
- MX2019014483A MX2019014483A MX2019014483A MX2019014483A MX2019014483A MX 2019014483 A MX2019014483 A MX 2019014483A MX 2019014483 A MX2019014483 A MX 2019014483A MX 2019014483 A MX2019014483 A MX 2019014483A MX 2019014483 A MX2019014483 A MX 2019014483A
- Authority
- MX
- Mexico
- Prior art keywords
- gonadotropin
- endometriosis
- dosing regimens
- releasing hormone
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Reproductive Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Gynecology & Obstetrics (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pregnancy & Childbirth (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Apparatus For Radiation Diagnosis (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762515268P | 2017-06-05 | 2017-06-05 | |
| PCT/EP2018/064768 WO2018224498A1 (en) | 2017-06-05 | 2018-06-05 | Gonadotropin-releasing hormone antagonist dosing regimens for the treatment of endometriosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2019014483A true MX2019014483A (es) | 2020-08-17 |
Family
ID=62620835
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019014483A MX2019014483A (es) | 2017-06-05 | 2018-06-05 | Regimenes de dosificación de antagonistas de hormona liberadora de gonadotropina para el tratamiento de endometriosis. |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US11980621B2 (https=) |
| EP (1) | EP3634418A1 (https=) |
| JP (2) | JP7348171B2 (https=) |
| KR (2) | KR102839190B1 (https=) |
| CN (1) | CN110996956A (https=) |
| AU (2) | AU2018280742B2 (https=) |
| CA (1) | CA3066190A1 (https=) |
| EA (1) | EA201992612A1 (https=) |
| MA (1) | MA49256A (https=) |
| MX (1) | MX2019014483A (https=) |
| SG (1) | SG11201911598WA (https=) |
| WO (1) | WO2018224498A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3518933B2 (en) | 2016-09-30 | 2025-02-26 | Sumitomo Pharma Switzerland GmbH | Methods of treating uterine fibroids and endometriosis |
| SG11201911598WA (en) | 2017-06-05 | 2020-01-30 | ObsEva SA | Gonadotropin-releasing hormone antagonist dosing regimens for the treatment of endometriosis |
| SG11201911599XA (en) | 2017-06-05 | 2020-01-30 | ObsEva SA | Gonadotropin-releasing hormone antagonist dosing regimens for treating uterine fibroids and reducing menstrual blood loss |
| CA3117092A1 (en) | 2018-10-29 | 2020-05-07 | ObsEva S.A. | Compositions and methods for the treatment of adenomyosis and rectovaginal endometriosis |
| AU2020325655B2 (en) * | 2019-08-08 | 2025-09-11 | Kissei Pharmaceutical Co., Ltd. | Compositions and methods for the treatment of estrogen-dependent disorders |
| CN113384581B (zh) * | 2020-03-12 | 2023-11-14 | 成都倍特药业股份有限公司 | 一种包含促性腺激素释放激素拮抗剂的药物组合物 |
| BR112022023937A2 (pt) | 2020-05-29 | 2022-12-27 | Myovant Sciences Gmbh | Formas de dosagem oral sólidas de combinação de antagonistas do hormônio liberador de gonadotropina |
| EP4243829A1 (en) * | 2020-11-11 | 2023-09-20 | Myovant Sciences GmbH | Methods of administering relugolix |
| CN116940575A (zh) * | 2021-02-23 | 2023-10-24 | 深圳市康哲药业有限公司 | 噻吩并嘧啶二酮类化合物及其应用 |
| CN115232144B (zh) * | 2021-04-22 | 2024-04-02 | 长春金赛药业有限责任公司 | 含氮稠环类衍生物、药物组合物及其制备方法和应用 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5342760A (en) | 1992-06-10 | 1994-08-30 | Abbott Laboratories | Determination of estradiol by competitive immunoassay |
| US5663054A (en) | 1995-03-03 | 1997-09-02 | Abbott Laboratories | Determination of steroids by competitive immunoassay |
| US7109171B2 (en) | 2000-02-28 | 2006-09-19 | Praecis Pharmaceuticals Inc. | Methods for treating FSH related conditions with GnRH antagonists |
| US6960591B2 (en) | 2000-07-05 | 2005-11-01 | Yamanouchi Pharmaceutical Co., Ltd. | Propane-1,3-dione derivative |
| EP1591446B1 (en) | 2003-01-29 | 2013-03-06 | Takeda Pharmaceutical Company Limited | Thienopyrimidine compounds and use thereof |
| AU2004257639B2 (en) | 2003-07-07 | 2011-01-06 | Neurocrine Biosciences, Inc. | Pyrimidine-2, 4-dione derivatives as gonadotropin-releasing hormone receptor antagonists |
| EP1864976B1 (en) | 2005-03-31 | 2012-10-10 | Astellas Pharma Inc. | Propane-1,3-dion derivative or salt thereof |
| PL1939204T6 (pl) * | 2005-10-19 | 2024-03-25 | Kissei Pharmaceutical Co., Ltd. | Skondensowana pochodna heterocykliczna, zawierająca ją kompozycja oraz jej zastosowanie medyczne |
| US8765948B2 (en) | 2007-11-07 | 2014-07-01 | Neurocrine Biosciences, Inc. | Processes for the preparation of uracil derivatives |
| JP5337261B2 (ja) | 2010-02-10 | 2013-11-06 | キッセイ薬品工業株式会社 | 縮合複素環誘導体の塩及びその結晶 |
| EA201491344A1 (ru) | 2012-01-16 | 2015-04-30 | Байер Интеллектуэль Проперти Гмбх | Производные спироиндолина в качестве антагонистов рецептора гонадотропин-рилизинг гормона |
| WO2013126517A1 (en) | 2012-02-21 | 2013-08-29 | Northwestern University | Anti-mullerian hormone detection in whole blood |
| WO2014038663A1 (ja) | 2012-09-07 | 2014-03-13 | アステラス製薬株式会社 | スルホニルアミジン化合物の製造法 |
| WO2014042176A1 (ja) | 2012-09-14 | 2014-03-20 | キッセイ薬品工業株式会社 | 縮合複素環誘導体の製造方法およびその製造中間体 |
| PL2900675T3 (pl) | 2012-09-28 | 2019-08-30 | Takeda Pharmaceutical Company Limited | Sposób wytwarzania pochodnej tienopirymidyny |
| IL241595B2 (en) | 2013-03-15 | 2025-10-01 | Abbvie Inc | Composition for use in methods of treating heavy menstrual bleeding associated with uterine fibroids |
| AR095785A1 (es) | 2013-04-09 | 2015-11-11 | Bayer Pharma AG | Derivados de espiroindolina y composiciones farmacéutica de los mismos |
| US9949974B2 (en) | 2015-09-01 | 2018-04-24 | Abbvie Inc. | Methods of adminstering elagolix |
| UA123114C2 (uk) | 2016-08-08 | 2021-02-17 | Кіссеі Фармасьютікал Ко., Лтд. | СПОСІБ ЛІКУВАННЯ ЕНДОМЕТРІОЗУ 3-[2-ФТОР-5-(2,3-ДИФТОР-6-МЕТОКСИБЕНЗИЛОКСИ)-4-МЕТОКСИФЕНІЛ]-2,4-ДІОКСО-1,2,3,4-ТЕТРАГІДРОТІЄНО[3,4-d]ПІРИМІДИН-5-КАРБОНОВОЮ КИСЛОТОЮ |
| EP3518933B2 (en) | 2016-09-30 | 2025-02-26 | Sumitomo Pharma Switzerland GmbH | Methods of treating uterine fibroids and endometriosis |
| SG11201911598WA (en) | 2017-06-05 | 2020-01-30 | ObsEva SA | Gonadotropin-releasing hormone antagonist dosing regimens for the treatment of endometriosis |
| SG11201911599XA (en) | 2017-06-05 | 2020-01-30 | ObsEva SA | Gonadotropin-releasing hormone antagonist dosing regimens for treating uterine fibroids and reducing menstrual blood loss |
| SG11202104053TA (en) | 2018-11-07 | 2021-05-28 | ObsEva SA | Compositions and methods for the treatment of estrogen-dependent disorders |
-
2018
- 2018-06-05 SG SG11201911598WA patent/SG11201911598WA/en unknown
- 2018-06-05 JP JP2020516959A patent/JP7348171B2/ja active Active
- 2018-06-05 KR KR1020197038977A patent/KR102839190B1/ko active Active
- 2018-06-05 MA MA049256A patent/MA49256A/fr unknown
- 2018-06-05 AU AU2018280742A patent/AU2018280742B2/en active Active
- 2018-06-05 CN CN201880050650.3A patent/CN110996956A/zh active Pending
- 2018-06-05 EP EP18731378.8A patent/EP3634418A1/en active Pending
- 2018-06-05 US US16/619,776 patent/US11980621B2/en active Active
- 2018-06-05 KR KR1020257024754A patent/KR20250117836A/ko active Pending
- 2018-06-05 WO PCT/EP2018/064768 patent/WO2018224498A1/en not_active Ceased
- 2018-06-05 CA CA3066190A patent/CA3066190A1/en active Pending
- 2018-06-05 EA EA201992612A patent/EA201992612A1/ru unknown
- 2018-06-05 MX MX2019014483A patent/MX2019014483A/es unknown
-
2023
- 2023-05-23 JP JP2023084336A patent/JP7657855B2/ja active Active
-
2024
- 2024-03-14 AU AU2024201701A patent/AU2024201701B2/en active Active
- 2024-04-12 US US18/634,241 patent/US20240293414A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP7657855B2 (ja) | 2025-04-07 |
| WO2018224498A1 (en) | 2018-12-13 |
| CA3066190A1 (en) | 2018-12-13 |
| EP3634418A1 (en) | 2020-04-15 |
| JP2023113715A (ja) | 2023-08-16 |
| JP7348171B2 (ja) | 2023-09-20 |
| EA201992612A1 (ru) | 2020-05-20 |
| MA49256A (fr) | 2021-05-26 |
| CN110996956A (zh) | 2020-04-10 |
| US20200138819A1 (en) | 2020-05-07 |
| JP2020522571A (ja) | 2020-07-30 |
| KR20250117836A (ko) | 2025-08-05 |
| AU2018280742A1 (en) | 2020-01-30 |
| SG11201911598WA (en) | 2020-01-30 |
| KR20200027481A (ko) | 2020-03-12 |
| US20240293414A1 (en) | 2024-09-05 |
| AU2024201701A1 (en) | 2024-04-04 |
| AU2018280742B2 (en) | 2023-12-21 |
| US11980621B2 (en) | 2024-05-14 |
| AU2024201701B2 (en) | 2025-04-10 |
| KR102839190B1 (ko) | 2025-07-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2019014483A (es) | Regimenes de dosificación de antagonistas de hormona liberadora de gonadotropina para el tratamiento de endometriosis. | |
| JOP20200116B1 (ar) | طرق لعلاج أو الوقاية من الصداع النصفي | |
| PH12017502079A1 (en) | Treatment of beta-thalassemia using actrii ligand traps | |
| MX2021000071A (es) | Uso de pridopidina para mejorar la funcion cognitiva y para tratamiento de enfermedad de alzheimer. | |
| PH12017502103A1 (en) | Methods and kits for treating depression | |
| MX385287B (es) | Anticuerpos anti-puntos de control inmunitarios para usarse en el tratamiento de la enfermedad de alzheimer. | |
| MX2023008760A (es) | Terapia combinada de lasmiditan y un antagonista de cgrp para el uso en el tratamiento de la migra?a. | |
| MX2019001958A (es) | Metodos para tratar la enfermedad de crohn con un anticuerpo anti-nkg2d. | |
| MX2022014634A (es) | Metodos para la administracion linfatica de agentes activos. | |
| PH12020551018A1 (en) | Oral delivery of glp-1 peptide analogs | |
| EA201791227A1 (ru) | РЕЖИМ ДОЗИРОВАНИЯ АНТАГОНИСТОВ MAdCAM | |
| MX2019010982A (es) | Uso de receptores de diseño activados exclusivamente mediante fármacos de diseño en el tratamiento de trastornos convulsivos. | |
| GEP20207096B (en) | Substituted 2-thioxo-imidazolidin-4-ones and spiro analogues thereof, active anti-cancer ingredient, pharmaceutical com¬position, medicinal prepara¬tion, method for treating prostate cancer | |
| ZA202400851B (en) | Dosing regimens associated with extended release paliperidone injectable formulations | |
| MX2024009188A (es) | Regimenes de dosificacion asociados con formulaciones inyectables de paliperidona de liberacion prolongada. | |
| MX2022007315A (es) | Formulaciones de olanzapina de liberacion sostenida. | |
| MX2023006368A (es) | Regimenes de dosificacion asociados con formulaciones inyectables de paliperidona de liberacion prolongada. | |
| PH12019500075A1 (en) | Dosage regimens of lingo-1 antagonists and uses for treatment of demyelinating disorders | |
| PH12018500814A1 (en) | Oxadiazaspiro compounds for the treatment of drug abuse and addiction | |
| MX2016012722A (es) | Metodos para tratar el virus de la hepatitis c. | |
| MX2019011692A (es) | Nuevo tratamiento de enfermedades mitocondriales. | |
| ZA202002107B (en) | Use of specific sirna against protein s for the treatment of hemophilia | |
| PH12019502145A1 (en) | Agent for preventing myopia, treating myopia, and/or preventing myopia progression comprising tiotropium as active ingredient | |
| NZ734845A (en) | Use of short synthetic peptide for the treatment and/or prophylaxis of dry eye disease | |
| PH12017501918A1 (en) | Multi-peptide composition |